Drug Type Monoclonal antibody |
Synonyms 重组人源化抗IL17A单克隆抗体 (上海三生国健), 608, SSGJ-608 |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 3 | CN | 03 Jan 2023 | |
Non-radiographic axial spondyloarthritis | Phase 2 | CN | 18 Mar 2024 | |
AS | Phase 2 | CN | 27 Feb 2024 | |
Autoimmune Diseases | Phase 2 | CN | 30 Jan 2022 | |
AxSpA | IND Application | CN | 23 Jun 2022 |
NCT05536726 (NEWS) Manual | Phase 3 | - | 608:160 mg W0+80 mg Q2W+80mg Q4W | diaqlmbrof(qvthlcwqgf) = nwgkeulxkw yqeziexcvi (nnsqrzorhn ) Met View more | Positive | 02 Aug 2024 | |
608:160 mg Q4W+160mg Q8W | diaqlmbrof(qvthlcwqgf) = hxzlpjitny yqeziexcvi (nnsqrzorhn ) Met View more |